Richard Markus of Amgen take the stage with Carly Helfand of FiercePharma to delve into the development of biosimilars and Amgen’s use and place in the pharmaceutical landscape.

*This session was produced by our underwriter Amgen, and not The Atlantic’s editorial team.


Grounded in the 160-year legacy of the magazine, AtlanticLIVE brings the unparalleled journalism of The Atlantic to life through singular event experiences, on stage and off.

For more information, please visit: [ Ссылка ]

свернуть